Literature DB >> 12073559

[Risk factor for invasive zygomycosis in patients with hematologic malignancies].

V Rickerts1, Angelika Böhme, Gudrun Just-Nübling.   

Abstract

Zygomycosis (mucormycosis) is a relatively uncommon infection in immunocompromised patients most often diagnosed in patients with haematological malignancies and neutropenia. Postmortem series demonstrate a high mortality rate up to 80%. Pulmonary involvement mimicking the more frequently diagnosed invasive aspergillosis is the typical clinical presentation. Other risk factors for the development of zygomycosis that have been described in other patient populations include diabetic ketoacidosis, iron overload, use of deferoxamine and steroids. If these factors are also associated with zygomycosis in patients with haematological malignancies has not been described. In a retrospective case-control study including 13 patients with zygomycosis and 13 control patients with the same underlying diseases, without zygomycosis we determined the frequency of various risk factors. Patients with zygomycosis experienced a longer period of neutropenia (17 vs. 13 days) and lymphopenia (23 vs. 20 days). A relapse of their underlying disease was diagnosed more frequently in patients with zygomycosis (7/13 vs. 3/13) as were a diagnosis of diabetes mellitus (6/13 vs. 3/13) and a cardiovascular disease (6/13 vs. 1/13). The previous use of steroids was more frequent in patients with zygomycosis (8/13 vs. 4/13) as was a systemic antifungal prophylaxis with itraconazole (9/13 vs. 4/13). Knowledge of these risk factors may be of benefit in diagnosing and monitoring zygomycosis in patients with haematological malignancies.

Entities:  

Mesh:

Year:  2002        PMID: 12073559     DOI: 10.1111/j.1439-0507.2002.tb04542.x

Source DB:  PubMed          Journal:  Mycoses        ISSN: 0933-7407            Impact factor:   4.377


  8 in total

Review 1.  Mucormycosis, pseudallescheriasis, and other uncommon mold infections.

Authors:  Clifford Quan; Brad Spellberg
Journal:  Proc Am Thorac Soc       Date:  2010-05

2.  Mucormycosis presenting as recurrent gastric perforation in a patient with Crohn's disease on glucocorticoid, 6-mercaptopurine, and infliximab therapy.

Authors:  Shane M Devlin; Bing Hu; Andrew Ippoliti
Journal:  Dig Dis Sci       Date:  2007-04-04       Impact factor: 3.199

3.  Impact of zygomycosis on microbiology workload: a survey study in Spain.

Authors:  Marta Torres-Narbona; Jesús Guinea; José Martínez-Alarcón; Patricia Muñoz; Ignacio Gadea; Emilio Bouza
Journal:  J Clin Microbiol       Date:  2007-03-28       Impact factor: 5.948

Review 4.  Novel perspectives on mucormycosis: pathophysiology, presentation, and management.

Authors:  Brad Spellberg; John Edwards; Ashraf Ibrahim
Journal:  Clin Microbiol Rev       Date:  2005-07       Impact factor: 26.132

5.  Recent advances in the treatment of mucormycosis.

Authors:  Brad Spellberg; Ashraf S Ibrahim
Journal:  Curr Infect Dis Rep       Date:  2010-11       Impact factor: 3.725

6.  Hard palate perforation in acute lymphoblastic leukemia due to mucormycosis - a case report.

Authors:  Dipti R Samanta; Surendra N Senapati; Praveen K Sharma; B S Shruthi; Prajna Bimoch Paty; Gitanjali Sarangi
Journal:  Indian J Hematol Blood Transfus       Date:  2009-04-06       Impact factor: 0.900

Review 7.  Recent advances in the management of mucormycosis: from bench to bedside.

Authors:  Brad Spellberg; Thomas J Walsh; Dimitrios P Kontoyiannis; John Edwards; Ashraf S Ibrahim
Journal:  Clin Infect Dis       Date:  2009-06-15       Impact factor: 9.079

Review 8.  Recommendations for Risk Categorization and Prophylaxis of Invasive Fungal Diseases in Hematological Malignancies: A Critical Review of Evidence and Expert Opinion (TEO-4).

Authors:  Can Boğa; Zahit Bolaman; Seçkin Çağırgan; İhsan Karadoğan; Mehmet Ali Özcan; Fahir Özkalemkaş; Rabin Saba; Mehmet Sönmez; Esin Şenol; Hamdi Akan; Murat Akova
Journal:  Turk J Haematol       Date:  2015-06       Impact factor: 1.831

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.